Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: 68 Ga-Pentixafor PET/CT targets CXCR4 receptors and provides superior diagnostic accuracy in multiple myeloma (MM) compared with 18 F-FDG PET/CT. However, its role in response evaluation remains unexplored. We propose a 68 Ga-Pentixafor PET/CT-based response evaluation criterion and evaluate its utility compared with International Myeloma Working Group (IMWG) criteria and 18 F-FDG PET/CT-based response.
Patients And Methods: In this prospective single-center study, 40 treatment-naive myeloma patients were recruited between February 2021 and April 2023. Both 68 Ga-Pentixafor and 18 F-FDG PET/CT were performed at baseline and at follow-up (7.2 mo-median). Response to treatment was evaluated using the proposed 68 Ga-Pentixafor PET/CT criteria and compared with responses assessed by IMWG and 18 F-FDG PET/CT. Progression-free survival (PFS) and overall survival (OS) were analyzed and compared using Kaplan-Meier survival curves.
Results: Among the 40 newly diagnosed MM patients [median age: 56.5 years (IQR 45.25 to 63.75); 24 men], 68 Ga-Pentixafor PET/CT was positive in a greater proportion of patients than 18 F-FDG PET/CT [90% (36/40) vs. 67.5% (27/40); P =0.02] thus, adequately evaluated response in additional 27.5% (11/40) of cases. Using the proposed criteria for 68 Ga-Pentixafor PET/CT, significant differences in PFS were observed across response categories [complete response (CR)-not reached, partial response (PR)-26.2 mo, progressive disease (PD)-15.3 mo; P =0.001]. Among patients achieving ≥very good partial response (VGPR) as per IMWG, those with positive 68 Ga-Pentixafor PET/CT had shorter PFS compared with those with negative findings (median PFS: 34.2 mo vs. not reached; P =0.056), whereas no significant difference was noted with 18 F-FDG PET/CT ( P =0.68). In addition, on follow-up of patients with negative 18 F-FDG at the response, those with discordant 68 Ga-Pentixafor findings had significantly shorter PFS (17.73 mo vs. not reached; P =0.010) compared with those with concordant negative findings.
Conclusions: 68 Ga-Pentixafor PET/CT offers a more accurate assessment of treatment response and prognosis in MM patients, adding valuable information beyond the IMWG and 18 F-FDG PET/CT-based criteria.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000005731 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Synthesis, preclinical evaluation and clinical application of a novel heterodimeric tracer Ga-pentixafor-c(RGDfK) for PET-CT imaging.
Eur J Nucl Med Mol Imaging
September 2025
Department of PET-CT/MRI, NHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin, 150081, Heilongjiang, China.
Objective: CXCR4 and integrin αβ play important roles in tumor biology and are highly expressed in multiple types of tumors. This study aimed to synthesize, preclinically evaluate, and clinically validate a novel dual-targeted PET imaging probe Ga-pentixafor-c(RGDfK) for its potential in imaging tumors.
Methods: The effects of Ga-pentixafor-c(RGDfK) on cell viability, targeting specificity, and affinity were assessed in the U87MG cells.
Is CXCR4-targeted Ga-pentixafor PET/CT a reliable AVS-free modality for surgical decision-making and prognostic prediction in primary aldosteronism with bilateral adrenal lesions?
EJNMMI Res
August 2025
Department of Urology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, P.R. China.
Background: For patients diagnosed with primary aldosteronism (PA) accompanied by bilateral adrenal lesions, identifying optimal candidates for surgical intervention remains a significant clinical challenge. Although adrenal venous sampling (AVS) is currently the gold standard for lateralizing aldosterone hypersecretion, its technical complexity, invasiveness, and interpretive difficulties restrict its widespread adoption. In this study, we aimed to investigate the clinical application of Ga-pentixafor positron emission tomography/computed tomography (PET/CT) as a non-invasive imaging modality in AVS-free surgical decision-making for PA patients with bilateral adrenal lesions.
View Article and Find Full Text PDFEvaluating the diagnostic utility of [⁶⁸Ga]Ga-Pentixafor in solid tumors: a systematic review.
Ann Nucl Med
August 2025
Department of Nuclear Medicine, King Hussein Cancer Center (KHCC), Amman, Jordan.
The C-X-C motif chemokine receptor 4 (CXCR4) has emerged as a critical molecular imaging target in various malignancies due to its central role in tumor progression, metastasis, and resistance to therapy. Among the imaging modalities developed to exploit this target, [68Ga]Ga-Pentixafor-a positron emission tomography (PET) radiopharmaceutical-has shown potential in diagnostic imaging. However, its diagnostic utility in solid tumors remains relatively underexplored, particularly in comparison to the widely utilized [18F]fluorodeoxyglucose ([18F]FDG) PET/CT.
View Article and Find Full Text PDFThe utility of 68Ga-pentixafor PET/CT in superselective adrenal artery embolization(SAAE) for treating aldosterone adenomas.
Eur J Nucl Med Mol Imaging
August 2025
Department of Cardiology, Binhai Campus of the First Affiliated Hospital, National Regional Medical Center, Fujian Medical University, Fuzhou, People's Republic of China.
Purpose: Expression of CXC chemokine receptor 4 (CXCR4) has proved to be a valuable tool for guiding the diagnosis and treatment of aldosterone-producing adenoma (APA). In this study, we evaluated whether CXCR4 imaging with Ga-pentixafor PET/CT shows significant changes after superselective adrenal artery embolization (SAAE).
Methods: We prospectively recruited 25 patients with clinically diagnosed APA.
Ga-pentixafor for PET imaging of chemokine receptor 4 expression in lymphoproliferative diseases and solid tumors.
Hell J Nucl Med
August 2025
Department of Nuclear Medicine, State Key Laboratory of Common Mechanism Research for Major Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing, China.
Objective: Gallium-68 (Ga)-pentixafor, a novel positron emission tomography (PET) tracer with high affinity for C-X-C motif chemokine receptor 4 (CXCR4), has recently been introduced in order to assess the CXCR4 expression status in vivo. This study is to investigate the role of Ga-pentixafor in detecting various tumors with mice models and to provide references to clinical studies.
Materials And Methods: Gallium-68-pentixafor and fluorine-18-fluorodeoxyglucose (F-FDG) PET was performed in opm-2 (lymphoma), daudi (myeloma) and panc1 (pancreatic cancer)-bearing mice.